H1 25 Results Confirm the Relevance of Roquette’s Strategy
-
最新报道：Roquette reported H1 2025 turnover growth of 4% to €2.37 billion and an 18% EBITDA increase to €294 million, driven by the IFF Pharma Solutions acquisition and favorable product mix. The company's EBITDA margin rose 150 basis points to 12.4%, supported by disciplined cost management and strong performance in food and nutrition segments. CEO Thierry Fournier highlighted the successful integration of IFF Pharma Solutions and the complementary strengths of Roquette's two business groups.
下一篇
Kitron: Change in corporate management team
- Kitron ASA announces that Chief Operating Officer Kristoffer Asklöv has resigned to become...
24小时热点
热点专题
418154